Literature DB >> 17007064

Is acute dyspnea related to oxaliplatin administration?

L M Pasetto1, S Monfardini.   

Abstract

The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin. Oxaliplatin improves the efficacy of this combination in patients with stage III colon cancer and moreover its toxicity is well tolerable. We describe a rare clinical case of acute dyspnoea probably related to oxaliplatin at one month from the end of the adjuvant treatment. A 74-year-old man developed a locally advanced sigmoid carcinoma (pT3N1M0). A port a cath attached to an open-ended catheter was implanted in order to administer primary chemotherapy safely according to the FOLFOX4 schedule. One month following the end of the 6th cycle, the patient referred a persistent cough and moderate dyspnoea. Chest radiography displayed a change in the lung interstitium, chest CT scan confirmed this aspect of adult respiratory distress syndrome, spirometry reported a decreased carbon monoxide diffusion capacity. Antibiotic and corticosteroids were administered for 10 d, then a repeated chest X ray evidenced a progressive pulmonary infiltration. A transbronchial biopsy and cytology did not show an infective process, a CT scan reported radiological abnormalities including linear and nodular densities which were becoming confluents. Antimicotic and antiviral drugs did not evidence any benefit. The antiviral therapy was stopped and high dose metilprednisolone was started. The patient died of pulmonary distress after 10 d.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007064      PMCID: PMC4100679          DOI: 10.3748/wjg.v12.i36.5907

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  5 in total

Review 1.  NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.

Authors: 
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

2.  [Adjuvant treatment of colon cancer MOSAIC study's main results].

Authors:  Thierry André; Christophe Tournigand; Emmanuel Achille; Nicole Tubiana-Mathieu; Gérard Lledo; Yves Raoul; Elisabeth Carola; Michel Flesch; Thierry Muron; Arnaud Boutan-Laroze; Véronique Guérin Meyer; Catherine Boaziz; Michel Maigre; Gérard Ganem; Mireille Mousseau; Lamia Mounedji-Boudiaf; Aimery de Gramont
Journal:  Bull Cancer       Date:  2006-02-01       Impact factor: 1.276

3.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

4.  FDA drug approval summaries: oxaliplatin.

Authors:  Amna Ibrahim; Steven Hirschfeld; Martin H Cohen; Donna J Griebel; Grant A Williams; Richard Pazdur
Journal:  Oncologist       Date:  2004

5.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

  5 in total
  13 in total

1.  Fatal interstitial pneumonia associated with oxaliplatin-based therapy in a patient with metastatic rectal cancer.

Authors:  Satoshi Ishizone; Naohiko Koide; Noriyuki Akita; Fumitoshi Karasawa; Nobumitsu Kobayashi; Tomonobu Koizumi; Shinichi Miyagawa
Journal:  Clin J Gastroenterol       Date:  2011-03-24

2.  Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX).

Authors:  Katsuki Muneoka; Yoshio Shirai; Masataka Sasaki; Toshifumi Wakai; Jun Sakata; Katsuyoshi Hatakeyama
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

3.  Fatal pneumonitis induced by oxaliplatin.

Authors:  Sara Arévalo Lobera; Naiara Sagastibeltza Mariñelarena; Ibone Elejoste Echeberría; Mireia Melé Olivé; Larraitz Egaña Otaño; Laura Basterretxea Badiola; Adelaida La Casta Muñoa; Mikel Azkue Gabilondo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

4.  Oxaliplatin-induced lung injury with allergic reaction.

Authors:  Tetsuya Homma; Masatsugu Kurokawa; Yoshitaka Yamamoto; Satoshi Matsukura; Koushi Ieki; Shintaro Suzuki; Miho Odaka; Shin Watanabe; Munehiro Yamaguchi; Mitsuru Adachi
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

5.  Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy.

Authors:  Guillaume Le Baut; Jean-Marc Guilloit; Vincent Leprince; Yann Ollivier; Catherine Dubos-Arvis; Pascal Do; Jasmine Sutter; Ludovic Loge; Radj Gervais
Journal:  J Gastrointest Oncol       Date:  2018-06

6.  Oxaliplatin-induced lung fibrosis.

Authors:  Arpan Shah; Zarir F Udwadia; Sachin Almel
Journal:  Indian J Med Paediatr Oncol       Date:  2009-07

7.  Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports.

Authors:  Chun-Geun Ryu; Eun-Joo Jung; Gangmi Kim; Su Ran Kim; Dae-Yong Hwang
Journal:  J Korean Soc Coloproctol       Date:  2011-10-31

8.  Fatal pneumonitis induced by oxaliplatin: description of three cases.

Authors:  L B Pontes; D P D Armentano; A Soares; R C Gansl
Journal:  Case Rep Oncol       Date:  2012-02-29

9.  Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature.

Authors:  Mor Moskovitz; Mira Wollner; Nissim Haim
Journal:  Case Rep Oncol Med       Date:  2015-05-10

10.  Granulomatous lung disease requiring mechanical ventilation induced by a single application of oxaliplatin-based chemotherapy for colorectal cancer: a case report.

Authors:  Dane Wildner; Frank Boxberger; Axel Wein; Kerstin Wolff; Heinz Albrecht; Gudrun Männlein; Rolf Janka; Kerstin Amann; Jürgen Siebler; Werner Hohenberger; Markus F Neurath; Richard Strauß
Journal:  Case Rep Oncol Med       Date:  2013-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.